View clinical trials related to Dermatitis.
Filter by:This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with severe AD.
This is a randomized, double-blind, placebo-controlled Phase Ib clinical trial evaluating the safety tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of GR2002 Injection in patients with moderate to severe atopic dermatitis. The dosing period was 12 weeks and followed up to 20 weeks.
Clinical trials, specifically focused on atopic dermatitis, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.
The primary objective of the study was to evaluate the efficacy of 611 in Chinese adults with moderate to severe atopic dermatitis.
This study will investigate the tissue distribution of azithromycin in healthy, artificially inflamed and actually infected tissue of humans.
This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.
This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: - The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. - The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: - Be treated with either a low-dose or high-dose of JYP0061. - Undergo efficacy and safety evaluations as stipulated in the trial protocol.
This study aimed to evaluate reducing the incidence of radiation dermatitis by assigning hyperbaric oxygen therapy to patients with localized breast cancer.
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis